An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
2 Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia. michael.valenzuela@sydney.edu.au.
1 Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
2 Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia. michael.valenzuela@sydney.edu.au.
Alzheimer's disease (AD) represents arguably the most significant social, economic, and medical crisis of our time. Characterized by progressive neurodegenerative pathology, AD is first and foremost a condition of neuronal and synaptic loss. Repopulation and regeneration of depleted neuronal circuitry by exogenous stem cells is therefore a rational therapeutic strategy. This review will focus on recent advances in stem cell therapies utilizing animal models of AD, as well as detailing the human clinical trials of stem cell therapies for AD that are currently undergoing development.
Alzheimers Association 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332. doi: 10.1016/j.jalz.2015.02.003.
-
DOI
-
PubMed
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. doi: 10.1056/NEJMoa1304839.
-
DOI
-
PMC
-
PubMed
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50. doi: 10.1056/NEJMoa1210951.
-
DOI
-
PubMed
Walker D, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81:412–25. doi: 10.1002/jnr.20484.
-
DOI
-
PubMed
Delbeuck X, Van der Linden M, Collette F. Alzheimer’s disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79–92. doi: 10.1023/A:1023832305702.
-
DOI
-
PubMed
